Allgens(688613)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was CNY 45,892,651.03, representing a year-on-year increase of 25.10%[4] - The net profit attributable to shareholders decreased by 27.32% to CNY 13,148,745.08 compared to the same period last year[4] - Total operating revenue for Q1 2022 was CNY 45,892,651.03, an increase of 25.5% compared to CNY 36,686,118.23 in Q1 2021[20] - Net profit for Q1 2022 was CNY 11,205,537.61, a decrease of 35.2% from CNY 17,318,208.78 in Q1 2021[21] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.10, down from CNY 0.18 in Q1 2021[22] Research and Development - R&D expenses totaled CNY 18,387,296.71, accounting for 40.07% of operating revenue, an increase of 12.01 percentage points year-on-year[5] - R&D expenses for Q1 2022 were CNY 18,387,296.71, significantly higher than CNY 4,407,131.12 in Q1 2021, reflecting a focus on innovation[21] - The company established a joint research center with Tsinghua University for high-performance biomedical materials, resulting in increased R&D expenses[5] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 8,833,565.49, down 67.13% from the previous year[5] - The company reported a decrease in cash flow from operating activities, reflecting challenges in cash generation[23] - Cash received from sales and services in Q1 2022 was approximately ¥58.46 million, up from ¥39.78 million in Q1 2021, representing a growth of 46.9%[25] - Net cash flow from operating activities in Q1 2022 was ¥8.83 million, a decrease of 67.2% compared to ¥26.88 million in Q1 2021[25] - Cash and cash equivalents at the end of Q1 2022 totaled ¥363.57 million, down from ¥411.31 million at the beginning of the quarter, indicating a decrease of 11.6%[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,431,884,176.89, a slight increase of 0.41% from the end of the previous year[5] - The total liabilities for Q1 2022 were CNY 150,096,282.51, down from CNY 155,494,830.72 in Q1 2021[18] - The company holds non-current assets totaling RMB 305,380,078.84, which is a slight increase from RMB 305,190,726.17[16] - Total liabilities stood at ¥155.49 million, with current liabilities accounting for ¥55.18 million[29] Shareholder Information - The company has a significant shareholder, Jiaxing Huakong Investment Partnership, holding 12,976,445 shares, representing 9.73% of total shares[12] - The second-largest shareholder, Beijing Qilun Tianyou Venture Capital, holds 12,090,933 shares, accounting for 9.07%[12] Future Outlook - The company plans to continue investing in R&D and market expansion to drive future growth[21] - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[26] Other Information - The company has not disclosed any new product developments or technological advancements during this reporting period[14] - There are no significant mergers or acquisitions reported in the current quarter[14] - The company has not provided specific future guidance or market expansion strategies in this report[14]